PROSION

Please note: The information displayed on this page might be outdated.
PROSION: A pharmaceutical drug discovery company offering proline derived modules (ProMs) as the world’s first proline-rich-motive (PRM) structure mimicking building blocks. Based on its disruptive ProM-platform, PROSION develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. Among those targets is Ena/VASP, a marker of pancreatic & breast carcinogenesis and potential game-changer in oncology. For its first of many potential use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Pre-Clinical Stage
Disease Space
Cardiovascular, Oncology
Finance
Pre-Revenues
Industry
Life Sciences, Pharmaceuticals, Specialty Pharmaceutical
Listing
Private
Market Cap
Private
Therapeutic Modalities
pi3k, Platform Technology, Small Molecule
Website:
Profiles:
Address:
Vitalisstraße 67
Cologne, 50827
Germany

Company Participants at European Biotech Investor Days 2021

Slim Chiha
PROSION, Co-founder & CEO
Dr. Slim Chiha has been with the PROSION-project since its academic inception and has followed it as a lead research scientist in its many publicly funded phases. Prior to that, he has conducted training as a medicinal chemist at Bayer Healthcare and has also successfully completed the Executive Leadership Program at the University of Oxford. He is the winner of the 2020 Science4Life Venture Cup (Idea Phase) and is highly experienced in early-stage drug discovery and lead optimization. Slim holds a Ph.D. in Organic Chemistry from the University of Cologne and has co-authored several articles in high-ranking journals & granted patent applications.